New Holding Company Prepares Arkansas Mutual for Expansion
A.M. Best Co.’s succinct announcement that Arkansas Mutual Insurance Co. had achieved an A rating was the culmination of two years of work by the Arkansas-only medical malpractice carrier to get ahead of a changing market. “This now solidifies Arkansas Mutual for decades to come,” President Corey Little said last week. “It’s not pride: It’s what happens in every state with a home-state mutual.” Arkansas Mutual was formed eight years ago to create in-state competition for the out-of-state carriers that swept in when St. Paul Cos. abandoned the med-mal market completely in 2001. After starting from scratch, Arkansas Mutual now insures about 800 physicians in the state, Little said last week. 2015 revenue will be about $4 million, he said. But during the company’s short life, the doctoring business has changed dramatically. Doctors in Arkansas as elsewhere have been leaving individual practice in droves and becoming employees of hospital-owned clinics. “When we first went to see St. Bernards, they had four hospitalists on staff,” Little said of the Jonesboro health system. “Now they have 160 employed physicians.” Similarly, CARTI — Central Arkansas Radiation Therapy Institute Inc. — did not directly employ physicians until it acquired two physician groups, Little Rock Hematology &Oncology in December 2011 and Hematology Oncology Services of Arkansas in January 2013. Hospital bylaws typically ...
ConclusionsPRTB is only used in a minority of patients dying of PCa. The majority who die of PCa after PRTB do so within a year of their first course. The use of multifractionation was common in the last 4 weeks of life. Survival after first PRTB increased minimally over time, and additional research is required to identify its association with recent changes in practice. The referral rate and PRTB utilization rate differ between rural and nonrural locations, underlying the importance of accessibility and referral for utilization of PRTB. Investigating other barriers and ensuring equitable access to radiation are needed.
Data Presented at the 2019 Genitourinary Cancers Symposium Reinforces Benefits of Short Course of Treatment Using Stereotactic Body Radiation Therapy for Low- or Intermediate-Risk Prostate Cancer SUNNYVALE, Calif., Feb. 22, 2019 -- (Healthcare Sales &M... Devices, Oncology Accuray, stereotactic body radiation therapy
ConclusionSFRT for the management of MM painful bony metastases remains underutilized. Trends show that radiation oncologists do not appear to be changing their approach to treating this disease.
We report the results of a cohort of patients from a single center treated as part of the randomized phase-3 TARGIT-A trial.MethodsPatients ( ≥50 years) with cT1 cN0 cM0 and invasive ductal histology on biopsy were randomized between IORT with 20 Gy (arm-A) or postoperative whole-breast RT (WBRT) up to 56 Gy in 2 Gy fractions (arm-B). Postoperatively, patients in arm-A with multifocality, lymphovascular invasion, nodal invasion, extensive intraductal component, invasive lobular carcinoma, or resection margins
Radiation dermatitis is a common sequela of radiation therapy; up to 95% of patients will develop moderate-to-severe skin reactions. No gold-standard currently exists for the treatment of acute radiation-induced skin toxicity. It is, therefore, imperative to develop a greater understanding of management options available to allow clinicians to make informed decisions when managing radiation oncology patients. This literature review discusses the topical agents studied for the treatment of acute radiation dermatitis, reviews their mechanisms of action, and presents a treatment algorithm for clinicians managing patients suff...
Conclusions: In this study, 3R proved effective in terms of tumor volume reduction, rescue/preservation of neurological function, and limited ARE evolvement. PMID: 30783544 [PubMed]
Image-guided radiation therapy developer ViewRay has received clearance from...Read more on AuntMinnie.comRelated Reading: New orders drive ViewRay revenue growth in 2018 ViewRay adds to revenue and net loss in Q3 ViewRay to launch pancreatic cancer trial ViewRay taps new CCO ViewRay announces $150M stock offering
Proprietary Technology from ViewRay Enables Imaging and Treatment Enhancements CLEVELAND, Feb. 21, 2019 -- (Healthcare Sales &Marketing Network) -- ViewRay, Inc. (Nasdaq: VRAY), announced today that the company received 510(k) clearance from the U.S. ... Devices, Oncology, Radiology, FDA ViewRay, MRIdian, MRI-guided, radiotherapy
Hope et al.1 report on the impact of pretreatment 68Ga-PSMA-PET/CT or PET/MRI in the management of 45 patients with high-risk prostate cancer (PCA). Results of PSMA-PET/CTs were compared to the findings of CT scans and skeletal scintigraphy. Based on their data, PSMA-PET imaging resulted in changes of radiation therapy (RT) dose and volumes in 47% of the patients due to newly diagnosed N1/M1a disease. RT changes resulted in the extension of clinical target volume (CTV) covering the small pelvis and even the retroperitoneum or a RT boost to avid lymph nodes.
ConclusionsTo date, the short- and long-term performance of ADM in the context of postoperative radiation remains unclear. The objective of the present review will be to critically evaluate the literature with the intention of improving postoperative outcomes in the context of mastectomy and radiation.